United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics (Nasdaq: UTHR) announced the first transplant in its ongoing EXPAND clinical study of the investigational UKidney xenokidney in patients with end-stage renal disease on November 3, 2025. The operation was performed at NYU Langone Health. The UKidney used in the transplant is from a pig with 10 gene edits: six human genes added to improve immunologic compatibility and four porcine genes knocked out to reduce rejection risk and moderate organ growth.

The company described the trial as a first-of-its-kind effort to evaluate xenotransplantation as an alternative to lifelong dialysis, with stated emphasis on patient safety and continued scientific study.

United Therapeutics (Nasdaq: UTHR) reported record third quarter 2025 results with total revenue $799.5M (up 7% YoY) and net income $338.7M (up 10% YoY) for the quarter ended September 30, 2025.

Product highlights: Total Tyvaso sales were $478.0M (+10% YoY) driven by Tyvaso DPI growth; Orenitram sales were $131.1M (+16% YoY). R&D expense rose to $127.5M (+23% YoY).

Capital actions: The company completed accelerated share repurchases totaling about $2.0B aggregate, with ~2.64M shares delivered in Q3 2025 under ASR agreements.

United Therapeutics (Nasdaq: UTHR) will report third quarter 2025 financial results before market open on Wednesday, October 29, 2025. A press release with results will be issued at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time on the same day.

The live webcast and a one-year rebroadcast will be available at https://ir.unither.com/events-and-presentations. The company reiterates its public benefit corporation purpose and includes customary forward-looking statement cautionary language dated October 15, 2025.

United Therapeutics (Nasdaq: UTHR) announced it will feature clinical data and sponsor events at the CHEST 2025 Annual Meeting in Chicago, October 19–22, 2025.

Two oral rapid‑fire presentations on Oct 21, 2025: 10:44–10:48 AM CDT — interim PHINDER echocardiographic analysis; 2:03–2:07 PM CDT — impact of inhaled treprostinil initiation timing on hospitalizations in PH‑ILD.

Sponsored events include a fellows breakfast (Oct 18), Women in Chest Medicine luncheon (Oct 20), APP networking event (Oct 20), and a PHinding PH symposium (Oct 20, 6:00–9:00 PM CDT).

United Therapeutics (Nasdaq: UTHR) has announced a webcast to present data from their successful TETON-2 pivotal study of nebulized Tyvaso® for treating idiopathic pulmonary fibrosis (IPF). The presentation will take place on September 28, 2025, at 12:30 p.m. ET.

Dr. Steven D. Nathan, Chair of the TETON Steering Committee, will lead the presentation of data previously shown at the European Respiratory Society Congress. The study successfully met its primary endpoint, demonstrating improvement in absolute forced vital capacity (FVC) compared to placebo, with significant improvements also observed in most secondary endpoints.

United Therapeutics (Nasdaq: UTHR), a public benefit corporation, announced that CEO Martine Rothblatt will participate in a fireside chat at the Bernstein 2nd Annual Healthcare Forum in New York. The presentation is scheduled for September 23, 2025, from 1:10 p.m. to 1:50 p.m. EST.

Investors can access the session through a live webcast on the company's website, with a recorded version available for 90 days after the event. As a unique pharmaceutical company structured as a public benefit corporation, United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

United Therapeutics (NASDAQ:UTHR) announced its upcoming presentations at the European Respiratory Society (ERS) Congress in Amsterdam from September 27 - October 1, 2025. The company will showcase key clinical data including the phase 3 TETON-2 study results of inhaled treprostinil for idiopathic pulmonary fibrosis.

The presentations will feature multiple research findings, including interim data from the ADVANCE EXTENSION study evaluating ralinepag for pulmonary arterial hypertension, and discoveries from the PHINDER study focused on improving pulmonary hypertension detection in patients with interstitial lung disease. The congress will include oral presentations, poster sessions, and mini-symposia covering various aspects of United Therapeutics' commercial and development portfolio.

United Therapeutics (NASDAQ:UTHR) announced that its TETON-2 pivotal study of Tyvaso® (treprostinil) Inhalation Solution for treating idiopathic pulmonary fibrosis (IPF) has met its primary endpoint. The study demonstrated a significant improvement in forced vital capacity (FVC) of 95.6 mL compared to placebo at 52 weeks (p<0.0001).

The treatment showed benefits across all subgroups and achieved statistical significance in key secondary endpoints, including time to first clinical worsening event, percent predicted FVC, quality of life measures, and lung diffusion capacity. The safety profile was consistent with previous studies, with no new safety concerns identified.

United Therapeutics plans to use data from both TETON-2 and the ongoing TETON-1 study to support a supplemental New Drug Application for IPF indication. TETON-1 results are expected in the first half of 2026.

United Therapeutics (Nasdaq: UTHR), a public benefit corporation, announced that CFO James Edgemond will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The presentation is scheduled for September 8, 2025, from 3:20 PM to 3:55 PM EST.

The session will be accessible through a live webcast on the company's investor relations website, with a recorded version available for 90 days after the event. As a unique publicly-traded biotech company structured as a public benefit corporation (PBC), United Therapeutics focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.